NCT03809624 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT03809624
Title	Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer (PDL1x41BB)
Acronym	PDL1x41BB
Recruitment	Terminated
Gender	both
Phase	Phase II
Variant Requirements	Yes
Sponsors	Inhibrx, Inc.
Indications	renal cell carcinoma lung non-small cell carcinoma melanoma gastric adenocarcinoma Hodgkin's lymphoma Advanced Solid Tumor non-Hodgkin lymphoma transitional cell carcinoma gastroesophageal junction adenocarcinoma head and neck squamous cell carcinoma
Therapies	INBRX-105 INBRX-105 + Pembrolizumab
Age Groups:	adult \| senior
Covered Countries	USA

Additional content available in CKB BOOST